Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2025 |
|---|---|
| Revenue | — |
| R&D expense | $30.8M |
| Operating income | −$46.2M |
| Net income | −$43.4M |
| Cash & equivalents | $98.1M |
| Total debt | $1.4M |
| Operating cash flow | −$38.4M |
| Free cash flow | −$38.6M |
Company profile
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.